Presentation

Transgene is a French biotechnology company that utilises viral vector technology with the goal of indirectly or directly killing cancer cells. Transgene has two clinical-stage therapeutic vaccines: TG4001 for HPV-positive cancers, and TG4050, the first individualised therapeutic vaccine based on the myvac® platform, and two clinical-stage oncolytic viruses: TG6002 for solid tumours, and BT-001, the first oncolytic virus based on the Invir.IO™ platform.

Recent highlights
In January, Transgene announced a new collaboration with PersonGen to evaluate the likely synergistic mechanisms of PersonGen's TAA06 CAR-T cell injection and Transgene’s oncolytic virus from the Invir.IO™ platform in solid tumours. In April and June, Transgene continues to update positive preliminary data on two ongoing TG4050 Ph1 ovarian and head & neck cancer trials, with all evaluable head & neck cancer patients randomised to early treatment arm (n=8) still in complete response, two ovarian cancer patients showing stable diseases without relapse, and well tolerability with no serious AEs. In June, Transgene and BioInvent announced a clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®.

Outlook
The company aims to deliver data of Ph2 TG4001 interim analysis, Ph1 TG4050 additional data, and Ph1 TG6002 initial data by the end of 2022, and commence Ph1 bT-001 Part B combined with Pembrolizumab in H2 2022.